Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
22 September 2020 | Story Leonie Bolleurs | Photo Anja Aucamp
Every year, several of our staff and students are involved in projects in our community to make a positive difference. One of the projects where we are making a difference is at Bloemshelter.
I am because you are. Ubuntu. What better month do we have to celebrate our Ubuntu, our South Africanness, than September – Heritage Month. 

South Africans are known for their warm and generous spirit, their humanity. Closer to home, here at the University of the Free State, this is also a reality. 

Bettering the lives of others

Numerous staff members and students engage in community projects and partnerships. “As a regionally engaged university, the UFS supports development and social justice through the practice of engaged scholarship,” says Karen Venter, Head of the Division: Service Learning within the Directorate of Community Engagement.

Engaged scholarship occurs at the heart of community-university partnerships in close and co-operative interaction with several organisations in broader society for the common public good.

A few of the flagship partnership projects that come to mind are Bloemshelter (caring for the homeless and developing as a social enterprise); Towers of Hope (caring for the vulnerable and transforming the city); and the Princess Gabo Foundation (in Thaba ‘Nchu, where they obtained a zero teenage pregnancy rate in school with a simulating doll-parenting programme to initiate responsible reproductive health education). 

In Qwaqwa, Community Engagement partnerships involve the Itemoheleng Soy Project and the AGAPE Foundation for Community Development. Here, the development focuses on nutrition to boost people’s immune systems – especially during the COVID-19 pandemic. According to Moodi Matsoso from the Directorate: Community Engagement on our Qwaqwa Campus, the AGAPE Foundation is manufacturing rosehip juice, which helps with digestion and the healing of ulcers. 

Bishop Billyboy Ramahlele, Director of Community Engagement, is also passionate about sharing knowledge and skills regarding enterprise development to others, supporting them to reach their full potential with the building of tiny houses. 

According to him, an estimated 3 000 of our students are spending at least 127 000 hours per year engaging in the community through 73 academic service-learning modules, excluding the engagement of student organisations such as the Enactus UFS and co-curricular KOVSIE ACT (Active Civic Teaching) residential schools projects.

Vegetables for the food insecure

Another project that is making a difference not only in the lives of our students, but also for food-insecure families, is the UFS Community Garden Project. 

Kovsie ACT, in collaboration with Student Affairs and the university’s Centre for Sustainable Agriculture, Rural Development and Extension (CENSARDE), is running a project where they provide fresh vegetables, including cabbage, carrots, beetroot, kale, and peas to food-insecure families. 

Heritage Month is an ideal opportunity for everyone to show their Ubuntu spirit. Get involved and share some of your time, your talents, and your treasures to improve the lives of others.  There are several causes in Bloemfontein and Phuthaditjhaba that need support (clothes, food, blankets, toys, funding). 

You saw what some of our colleagues and students are doing. What are you doing to make a difference in communities?

- See Mandala Day poster for a complete list of the partnerships, programmes, and projects where our university’s Directorate of Community Engagement is making a difference. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept